Date: 2012-07-26
Type of information: Clinical research agreement
Compound: BRACAnalysis® (BRCA 1 and BRCA 2 testing)
Company: Myriad Genetics (USA) PharmaMar (Spain)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
services
Action mechanism: BRACAnalysis is a molecular diagnostic test developed by Myriad Genetics which analyzes the BRCA1 and BRCA2 genes to assess a woman\'s risk for developing breast and ovarian cancer and guide treatment decisions for women with hereditary breast and ovarian cancer.
Disease: ovarian cancer, breast cancer
Details: Myriad Genetics has signed an agreement with Pharma Mar, a leader in the development of marine-derived drugs. Under the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patients to be enrolled in a Phase II clinical study of PM1183, a novel drug candidate which induces double stranded DNA breaks to cause cell death. Under the agreement, Myriad will assess the BRCA status in patients who respond to PM01183. Myriad has entered into similar agreements with Abbott Pharmaceuticals , Astra Zeneca, BioMarin Pharmaceuticals and Cephalon to provide companion diagnostic testing with the BRACAnalysis® test for clinical trial enrollment.
Financial terms:
Latest news:
